Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 27.00
Bid: 26.00
Ask: 28.00
Change: 0.00 (0.00%)
Spread: 2.00 (7.692%)
Open: 27.00
High: 27.00
Low: 27.00
Prev. Close: 27.00
IKA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on fuel cell catalyst patent in Europe

13 Aug 2015 07:00

RNS Number : 9123V
Ilika plc
13 August 2015
 



13 August 2015

Ilika plc

("Ilika" or the "Company")

 

Update on fuel cell catalyst patent in Europe

 

Ilika (AIM: IKA), the accelerated materials innovation company, announces that the European Patent Office (EPO) has upheld Ilika's opposition to a fuel cell catalyst patent from Brookhaven Science Associates (BSA).

 

Certain claims of a granted European patent from Brookhaven Science Associates (BSA) might have impacted upon Ilika's freedom to operate its own granted European patent. BSA manages Brookhaven National Laboratory (BNL) on behalf of the United States Department of Energy (US DOE). BNL is a US national laboratory located in Upton, New York, on Long Island, primarily funded by the Office of Science of the US DOE.

 

Ilika had therefore filed an Opposition against the BSA patent in February 2013, and oral proceedings took place before the Opposition Division on 17th March 2015 at the European Patent Office (EPO) in Rijswijk, Netherlands. As a result of these proceedings, the BSA European patent was revoked. The EPO issued a notice on 8th August 2015 that the opposition proceedings were now terminated with revocation of the patent as the time limit had expired for filing an appeal against the decision to revoke the patent.

 

Ilika's patents underpin the product development work, which was supported by the Carbon Trust through the £150,000 equity investment Ilika announced in September 2012. The Carbon Trust invested in Ilika through its Polymer Fuel Cells Challenge programme to support the commercialization of Ilika's high performing electro-catalysts for use in fuel cell vehicles. As part of the Carbon Trust's technical and commercial evaluation of the technology, Ilika submitted performance data for assessment by independent experts demonstrating the performance and stability of the catalyst. The performance data was generated in industry standard tests of membrane electrode assemblies (MEA's) carried out at an independent fuel cell testing facility.

 

In December 2013, Ilika announced it had submitted positive cell performance data along with material samples for evaluation to three global OEM's. Initial trials were carried out by these OEM's in 2014 and Ilika continues to support evaluation trials by these three and other OEM's. The adoption rate of fuel cell technology has been historically difficult to predict and at present there is only a limited number of vehicles powered by fuel cells on the UK market. However, the first production Toyota Mirai models landed in Europe this week ahead of the official launch in September. The limited number of cars available in Britain is already sold out. The launch of this vehicle signals an increased focus by OEM's on cost-reduction of fuel cell technology with a view to enabling the mass market.

 

Commenting on this latest development, Graeme Purdy, Ilika CEO, said: "Ilika invests significantly in creating valuable intellectual property to underpin the growth of its business. Potentially competitive filings are monitored very closely and are challenged where appropriate. We welcome this development as we now enjoy freedom to operate our European patent in addition to our United States patent where there had never been such issues because of the different claims structures between the granted US patents of both BSA and Ilika. This positive outcome supports Ilika's commercialisation activities with interested OEM's."

 

 

  

 

 

For more information contact:

 

Ilika plc

www.ilika.com

Graeme Purdy, Chief Executive

Tel: 023 8011 1400

Steve Boydell, Finance Director

 

 

 

Numis Securities Limited

Tel: 020 7260 1000

Oliver Cardigan/ Adrian Trimmings /

 

James Black

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 / ilika@walbrookpr.com

Lianne Cawthorne (Media Enquiries)

Mob: 07584 391 303

Paul Cornelius (Investor Enquiries)

Mob: 07827 879460

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLFFFFTLIFLIE
Date   Source Headline
26th Aug 20207:00 amRNSStereax® manufacturing plans update
26th Aug 20207:00 amRNSAnnual Report & Notice of AGM
14th Aug 20203:56 pmRNSHolding(s) in Company
14th Aug 20202:06 pmRNSSecond Price Monitoring Extn
14th Aug 20202:01 pmRNSPrice Monitoring Extension
24th Jul 20202:06 pmRNSSecond Price Monitoring Extn
24th Jul 20202:01 pmRNSPrice Monitoring Extension
17th Jul 20202:06 pmRNSSecond Price Monitoring Extn
17th Jul 20202:00 pmRNSPrice Monitoring Extension
17th Jul 202011:06 amRNSSecond Price Monitoring Extn
17th Jul 202011:02 amRNSPrice Monitoring Extension
15th Jul 20204:42 pmRNSSecond Price Monitoring Extn
15th Jul 20204:37 pmRNSPrice Monitoring Extension
9th Jul 20207:00 amRNSFinal Results
16th Jun 20207:00 amRNSCOVID-19 Update, Facility Re-opening
10th Jun 20204:14 pmRNSHolding(s) in Company
10th Jun 202011:05 amRNSSecond Price Monitoring Extn
10th Jun 202011:00 amRNSPrice Monitoring Extension
9th Jun 20207:00 amRNSTrading Update & Notice of Results
8th Jun 20204:42 pmRNSSecond Price Monitoring Extn
8th Jun 20204:36 pmRNSPrice Monitoring Extension
20th Apr 20207:00 amRNSAppointment of Non-Executive Director
20th Apr 20207:00 amRNSCEO appointed as NED of Bacanora Lithium plc
6th Apr 20207:00 amRNSInvestor presentation
30th Mar 20204:25 pmRNSHolding(s) in Company
30th Mar 20202:40 pmRNSHolding(s) in Company
27th Mar 20205:26 pmRNSHolding(s) in Company
27th Mar 202010:58 amRNSHolding(s) in Company
27th Mar 20209:00 amRNSAward of Share Options, Exercise of Options & TVR
25th Mar 20201:45 pmRNSResults of General Meeting and Open Offer & TVR
25th Mar 202011:06 amRNSSecond Price Monitoring Extn
25th Mar 202011:01 amRNSPrice Monitoring Extension
25th Mar 20207:00 amRNSCOVID-19 Update
19th Mar 20204:15 pmRNSGeneral Meeting: Change of Venue
18th Mar 202011:07 amRNSSecond Price Monitoring Extn
18th Mar 202011:01 amRNSPrice Monitoring Extension
6th Mar 20205:20 pmRNSResult of Placing
6th Mar 20201:20 pmRNSProposed Placing & Open Offer
7th Feb 20207:00 amRNSGrowth & Innovation Forum 2020
4th Feb 20207:00 amRNSSuccessful Stereax Field Trial
23rd Jan 20207:00 amRNSHalf-year Report
15th Jan 202011:06 amRNSSecond Price Monitoring Extn
15th Jan 202011:01 amRNSPrice Monitoring Extension
14th Jan 20204:41 pmRNSSecond Price Monitoring Extn
14th Jan 20204:36 pmRNSPrice Monitoring Extension
13th Jan 202011:08 amRNSSecond Price Monitoring Extn
13th Jan 202011:05 amRNSPrice Monitoring Extension
10th Jan 20202:07 pmRNSSecond Price Monitoring Extn
10th Jan 20202:01 pmRNSPrice Monitoring Extension
2nd Jan 20204:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.